Reporter brief
Does Insulin Sensitivity Impact the Potential of Metformin to Slow Aging
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The results do not establish whether metformin slows aging; the study measured surrogate biomarkers and mitochondrial changes over 12 weeks, not clinical aging outcomes or lifespan extension. The study does not determine whether observed changes in insulin sensitivity or mitochondrial function persist beyond the 12-week intervention period or translate to health benefits. The stratification by baseline insulin sensitivity may have created selection bias that limits generalizability to unselected aging populations.
Study design and sample
Rct; Human.
148 subjects recruited from two sites (Oklahoma Medical Research Foundation and University of Wisconsin-Madison), free of type 2 diabetes, stratified to insulin sensitive or insulin resistant groups
- Design
- Rct
- Sample
- 148
- Journal
- Oklahoma Medical Research Foundation
- Published
- Jul 2, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.